Akèy › Limfòm folikilè › Texas › Houston
Etid klinik pou Limfòm folikilè nan Houston, TX
18 etid pou Limfòm folikilè ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
- Research Site, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Md Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Houston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Ap rekriteFaz 3
- Center for Oncology and Blood Disorders, Houston
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
- The University of TX MD Anderson Cancer Center, Houston
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Ap rekriteFaz 2
- Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
Etid Limfòm folikilè nan lòt vil
- New York City, NY24 etid
- Milwaukee, WI19 etid
- Nashville, TN18 etid
- Boston, MA17 etid
- Baldwin Park, CA16 etid
- Seattle, WA15 etid
- Durham, NC15 etid
- Columbus, OH13 etid
- Salt Lake City, UT13 etid
- San Antonio, TX12 etid
- Chicago, IL12 etid
- Philadelphia, PA12 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.